Prostate cancer · De novo metastatic HSPC · prostate RT
STAMPEDE Arm H
Does prostate RT improve outcomes in newly diagnosed metastatic disease, particularly low-burden disease?
Phase III RCT; n=2,061. Standard care (ADT ± docetaxel) vs standard care+prostate RT.
Arms / design
Phase III RCT; n=2,061. Standard care (ADT ± docetaxel) vs standard care+prostate RT.
Outcome visualization · source-reported data
3-year OS in low-burden subgroup
Low-burden OS HR 0.68 (95% CI 0.52–0.90); overall-population OS HR 0.92
Visualization reflects reported outcomes; it does not itself generate an NNT or establish an overall-survival benefit.
Key result
Benefit was concentrated in low metastatic burden; do not extrapolate to high-burden disease.
Interpretation and limitations
https://pubmed.ncbi.nlm.nih.gov/30355464/
Primary source
undefined